Compare DuPont de Nemours Inc (DD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Zimmer Biomet Holdings Inc — how do they compare? DuPont de Nemours Inc trades at $130 (market cap $17.89B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: DuPont de Nemours Inc and Zimmer Biomet Holdings Inc are close in size by market cap, and DuPont de Nemours Inc pays the higher dividend (1.81%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| DD | ZBH | |
|---|---|---|
Market Cap | $17.89B | $16.95B |
Volume | 816,409 | 2,505,240 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $103.98 |
52-Week Low | $92.49 | $79.58 |
Typical Hold Time | 89 Days | 89 Days |
Enterprise Value | $19.28B | $24.02B |
Dividend Yield | 1.81% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $132.48, up 1.07% with neutral technical signals. The company shows mixed fundamentals with strong recent earnings beats but declining revenue from $12.4B in 2024 to $6.85B in 2025, resulting in a net loss of $779M. Analyst consensus is bullish with 59% buy ratings, though the $95 consensus price target suggests downside risk. Recent developments include new product launches in sustainable materials and digital tools, alongside ongoing legal settlements related to PFAS contamination.
Outlook remains cautious due to revenue contraction and margin pressure, offset by innovation in high-growth sectors like healthcare and water technologies. Key risks include legal liabilities from PFAS lawsuits and volatile cash flows, while institutional sentiment appears divided with recent stake reductions by several funds.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
